Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 968

1.

The Microbiome Factor in Drug Discovery and Development.

Nuzzo A, Brown JR.

Chem Res Toxicol. 2019 Dec 5. doi: 10.1021/acs.chemrestox.9b00333. [Epub ahead of print]

PMID:
31802667
2.

Heart failure biomarker levels correlate with invasive haemodynamics in pulmonary valve replacement.

Zegelbone PM, Ringel RE, Coulson JD, Nies MK, Stabler ME, Brown JR, Everett AD.

Cardiol Young. 2019 Nov 27:1-5. doi: 10.1017/S1047951119002737. [Epub ahead of print]

PMID:
31771681
3.

Evolving Strategies in First-Line Chronic Lymphocytic Leukemia: Is There a Role for Chemoimmunotherapy?

Brown JR, Wierda WG.

J Natl Compr Canc Netw. 2019 Nov;17(11.5):1408-1410. doi: 10.6004/jnccn.2019.5026.

PMID:
31766019
4.

Phosphatidylinositol 3 Kinase δ Inhibitors: Present and Future.

Brown JR.

Cancer J. 2019 Nov/Dec;25(6):394-400. doi: 10.1097/PPO.0000000000000414.

PMID:
31764120
5.

Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL).

Lampson BL, Tyekucheva S, Crombie JL, Kim AI, Merryman RW, Lowney J, Montegaard J, Patterson V, Jacobson CA, Jacobsen ED, LaCasce AS, Arnason JE, Armand P, Fisher DC, Brown JR, Davids MS.

Blood. 2019 Nov 13;134(Supplement_1):32. doi: 10.1182/blood-2019-127506.

PMID:
31723987
6.

Chemo-immunotherapy for Older Patients with Chronic Lymphocytic Leukemia - Passé Yet?

Danilov AV, Pagel JM, Brown JR, Hill BT.

Hemasphere. 2019 Aug 7;3(4):e275. doi: 10.1097/HS9.0000000000000275. eCollection 2019 Aug. No abstract available.

7.

Comparative Performance of Prediction Models for Contrast-Associated Acute Kidney Injury After Percutaneous Coronary Intervention.

Ma B, Allen DW, Graham MM, Har BJ, Tyrrell B, Tan Z, Spertus JA, Brown JR, Matheny ME, Hemmelgarn BR, Pannu N, James MT.

Circ Cardiovasc Qual Outcomes. 2019 Nov;12(11):e005854. doi: 10.1161/CIRCOUTCOMES.119.005854. Epub 2019 Nov 14.

PMID:
31722540
8.

Role of Solvation on Diffusion of Ions in Diblock Copolymers: Understanding the Molecular Weight Effect through Modeling.

Seo Y, Shen KH, Brown JR, Hall LM.

J Am Chem Soc. 2019 Nov 20;141(46):18455-18466. doi: 10.1021/jacs.9b07227. Epub 2019 Nov 12.

PMID:
31674178
9.

Evaluation of non-reducing end pathologic glycosaminoglycan detection method for monitoring therapeutic response to enzyme replacement therapy in human mucopolysaccharidosis I.

Vera MU, Le SQ, Victoroff A, Passage MB, Brown JR, Crawford BE, Polgreen LE, Chen AH, Dickson PI.

Mol Genet Metab. 2019 Sep 11. pii: S1096-7192(19)30432-9. doi: 10.1016/j.ymgme.2019.09.001. [Epub ahead of print]

PMID:
31630958
10.

Nigral overexpression of α-synuclein in a rat Parkinson's disease model indicates alterations in the enteric nervous system and the gut microbiome.

O'Donovan SM, Crowley EK, Brown JR, O'Sullivan O, O'Leary OF, Timmons S, Nolan YM, Clarke DJ, Hyland NP, Joyce SA, Sullivan AM, O'Neill C.

Neurogastroenterol Motil. 2019 Oct 2:e13726. doi: 10.1111/nmo.13726. [Epub ahead of print]

PMID:
31576631
11.

Cardiovascular Toxicities Associated With Ibrutinib.

Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, Yang T, Reddy NM, Funck-Brentano C, Brown JR, Roden DM, Moslehi JJ.

J Am Coll Cardiol. 2019 Oct 1;74(13):1667-1678. doi: 10.1016/j.jacc.2019.07.056.

PMID:
31558250
12.

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.

Guièze R, Liu VM, Rosebrock D, Jourdain AA, Hernández-Sánchez M, Martinez Zurita A, Sun J, Ten Hacken E, Baranowski K, Thompson PA, Heo JM, Cartun Z, Aygün O, Iorgulescu JB, Zhang W, Notarangelo G, Livitz D, Li S, Davids MS, Biran A, Fernandes SM, Brown JR, Lako A, Ciantra ZB, Lawlor MA, Keskin DB, Udeshi ND, Wierda WG, Livak KJ, Letai AG, Neuberg D, Harper JW, Carr SA, Piccioni F, Ott CJ, Leshchiner I, Johannessen CM, Doench J, Mootha VK, Getz G, Wu CJ.

Cancer Cell. 2019 Oct 14;36(4):369-384.e13. doi: 10.1016/j.ccell.2019.08.005. Epub 2019 Sep 19.

PMID:
31543463
13.

Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study.

Ruchlemer R, Ben-Ami R, Bar-Meir M, Brown JR, Malphettes M, Mous R, Tonino SH, Soussain C, Barzic N, Messina JA, Jain P, Cohen R, Hill B, Mulligan SP, Nijland M, Herishanu Y, Benjamini O, Tadmor T, Okamoto K, Arthurs B, Gottesman B, Kater AP, Talha M, Eichhorst B, Korem M, Bogot N, De Boer F, Rowe JM, Lachish T.

Mycoses. 2019 Dec;62(12):1140-1147. doi: 10.1111/myc.13001. Epub 2019 Oct 22.

PMID:
31520441
14.

Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA.

Am J Hematol. 2019 Dec;94(12):1353-1363. doi: 10.1002/ajh.25638. Epub 2019 Oct 13.

PMID:
31512258
15.

Role of Sex in Determining Treatment Type for Patients Undergoing Endovascular Lower Extremity Revascularization.

Ramkumar N, Suckow BD, Brown JR, Sedrakyan A, MacKenzie T, Stone DH, Cronenwett JL, Goodney PP.

J Am Heart Assoc. 2019 Sep 3;8(17):e013088. doi: 10.1161/JAHA.119.013088. Epub 2019 Aug 31.

16.

Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.

Kipps TJ, Fraser G, Coutre SE, Brown JR, Barrientos JC, Barr PM, Byrd JC, O'Brien SM, Dilhuydy MS, Hillmen P, Jaeger U, Moreno C, Cramer P, Stilgenbauer S, Chanan-Khan AA, Mahler M, Salman M, Eckert K, Solman IG, Balasubramanian S, Cheng M, Londhe A, Ninomoto J, Howes A, James DF, Hallek M.

Clin Lymphoma Myeloma Leuk. 2019 Nov;19(11):715-722.e6. doi: 10.1016/j.clml.2019.07.004. Epub 2019 Jul 15.

17.

A comprehensive characterization of chronic norovirus infection in immunodeficient hosts.

Brown LK, Ruis C, Clark I, Roy S, Brown JR, Albuquerque AS, Patel SY, Miller J, Karim MY, Dervisevic S, Moore J, Williams CA, Cudini J, Moreira F, Neild P, Seneviratne SL, Workman S, Toumpanakis C, Atkinson C, Burns SO, Breuer J, Lowe DM.

J Allergy Clin Immunol. 2019 Nov;144(5):1450-1453. doi: 10.1016/j.jaci.2019.07.036. Epub 2019 Aug 13. No abstract available.

18.

Immunofluorescence and image analysis pipeline for Drosophila motor neurons.

Brown JR, Phongthachit C, Sulkowski MJ.

Biol Methods Protoc. 2019;4(1):bpz010. doi: 10.1093/biomethods/bpz010. Epub 2019 Aug 1.

19.

For CLL cells, there's no place like home.

Lampson BL, Brown JR.

Leuk Lymphoma. 2019 Aug 2:1-3. doi: 10.1080/10428194.2019.1646910. [Epub ahead of print] No abstract available.

PMID:
31373247
20.

In Silico Modeling of Biofilm Formation by Nontypeable Haemophilus influenzae In Vivo.

Brown JR, Jurcisek J, Lakhani V, Snedden A, Ray WC, Mokrzan EM, Bakaletz LO, Das J.

mSphere. 2019 Jul 31;4(4). pii: e00254-19. doi: 10.1128/mSphere.00254-19.

21.

Transforming Triplet Vinylnitrene into Triplet Alkylnitrene at Cryogenic Temperatures.

Shields DJ, Sarkar SK, Sriyarathne HDM, Brown JR, Wentrup C, Abe M, Gudmundsdottir AD.

Org Lett. 2019 Sep 20;21(18):7194-7198. doi: 10.1021/acs.orglett.9b01950. Epub 2019 Jul 26.

PMID:
31348664
22.

Galectin-3 as a Predictor of Long-term Survival After Isolated Coronary Artery Bypass Grafting Surgery.

Parker DM, Owens SL, Ramkumar N, Likosky D, DiScipio AW, Malenka DJ, MacKenzie TA, Brown JR.

Ann Thorac Surg. 2019 Jul 20. pii: S0003-4975(19)31038-0. doi: 10.1016/j.athoracsur.2019.05.072. [Epub ahead of print]

PMID:
31336070
23.

Novel Biomarkers Improves Prediction of 365-Day Readmission After Pediatric Congenital Heart Surgery.

Parker DM, Everett AD, Stabler ME, Vricella L, Jacobs ML, Jacobs JP, Parikh CR, Pasquali SK, Brown JR.

Ann Thorac Surg. 2019 Jul 16. pii: S0003-4975(19)31035-5. doi: 10.1016/j.athoracsur.2019.05.070. [Epub ahead of print]

PMID:
31323208
24.

The Association Between Cardiac Biomarker NT-proBNP and 30-Day Readmission or Mortality After Pediatric Congenital Heart Surgery.

Parker DM, Everett AD, Stabler ME, Leyenaar J, Vricella L, Jacobs JP, Thiessen-Philbrook H, Parikh C, Greenberg JH, Brown JR.

World J Pediatr Congenit Heart Surg. 2019 Jul;10(4):446-453. doi: 10.1177/2150135119842864.

PMID:
31307305
25.

Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia.

Giacopelli B, Zhao Q, Ruppert AS, Agyeman A, Weigel C, Wu YZ, Gerber MM, Rabe KG, Larson MC, Lu J, Blachly JS, Rogers KA, Wierda WG, Brown JR, Rai KR, Keating M, Rassenti LZ, Kipps TJ, Zenz T, Shanafelt TD, Kay NE, Abruzzo LV, Coombes KR, Woyach JA, Byrd JC, Oakes CC.

Blood. 2019 Aug 22;134(8):688-698. doi: 10.1182/blood.2019000490. Epub 2019 Jul 10.

26.

Biomarkers improve prediction of 30-day unplanned readmission or mortality after paediatric congenital heart surgery.

Brown JR, Stabler ME, Parker DM, Vricella L, Pasquali S, Leyenaar JK, Bohm AR, MacKenzie T, Parikh C, Jacobs ML, Jacobs JP, Everett AD.

Cardiol Young. 2019 Aug;29(8):1051-1056. doi: 10.1017/S1047951119001471. Epub 2019 Jul 10.

27.

Healthcare spending in the State of Louisiana.

Kruger BP, Brown JR.

BMC Health Serv Res. 2019 Jul 9;19(1):471. doi: 10.1186/s12913-019-4275-y.

28.

Cardiac Biomarkers Predict Long-term Survival After Cardiac Surgery.

Ramkumar N, Jacobs JP, Berman RB, Parker DM, MacKenzie TA, Likosky DS, DiScipio A, Malenka DJ, Brown JR.

Ann Thorac Surg. 2019 Dec;108(6):1776-1782. doi: 10.1016/j.athoracsur.2019.04.123. Epub 2019 Jun 27.

PMID:
31255614
29.

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report.

Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorror ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobecks R, Alyea E, Saber W, Brown JR.

Clin Cancer Res. 2019 Aug 15;25(16):5143-5155. doi: 10.1158/1078-0432.CCR-18-3988. Epub 2019 Jun 28.

PMID:
31253630
30.
31.

A multi-center analysis of readmission after cardiac surgery: Experience of The Northern New England Cardiovascular Disease Study Group.

Trooboff SW, Magnus PC, Ross CS, Chaisson K, Kramer RS, Helm RE, Desaulniers H, De La Rosa RC, Westbrook BM, Duquette D, Brown JR, Olmstead EM, Malenka DJ, Iribarne A.

J Card Surg. 2019 Aug;34(8):655-662. doi: 10.1111/jocs.14086. Epub 2019 Jun 18.

PMID:
31212387
32.

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.

Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, Hellman JM, Bazemore J, Francoeur K, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng S, Crombie J, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Fisher DC, Brown JR; Blood Cancer Research Partnership of the Leukemia & Lymphoma Society.

Lancet Haematol. 2019 Aug;6(8):e419-e428. doi: 10.1016/S2352-3026(19)30104-8. Epub 2019 Jun 14.

PMID:
31208944
33.

Airway host-microbiome interactions in chronic obstructive pulmonary disease.

Wang Z, Maschera B, Lea S, Kolsum U, Michalovich D, Van Horn S, Traini C, Brown JR, Hessel EM, Singh D.

Respir Res. 2019 Jun 6;20(1):113. doi: 10.1186/s12931-019-1085-z.

34.

Growth dynamics in naturally progressing chronic lymphocytic leukaemia.

Gruber M, Bozic I, Leshchiner I, Livitz D, Stevenson K, Rassenti L, Rosebrock D, Taylor-Weiner A, Olive O, Goyetche R, Fernandes SM, Sun J, Stewart C, Wong A, Cibulskis C, Zhang W, Reiter JG, Gerold JM, Gribben JG, Rai KR, Keating MJ, Brown JR, Neuberg D, Kipps TJ, Nowak MA, Getz G, Wu CJ.

Nature. 2019 Jun;570(7762):474-479. doi: 10.1038/s41586-019-1252-x. Epub 2019 May 29.

35.

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.

Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, Stephens DM, Woyach J, Bibikova E, Charuworn P, Frigault MM, Hamdy A, Izumi R, Linghu B, Patel P, Wang MH, Byrd JC.

Blood Adv. 2019 May 14;3(9):1553-1562. doi: 10.1182/bloodadvances.2018030007.

36.

Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia.

Soumerai JD, Davids MS, Werner L, Fisher DC, Armand P, Amrein PC, Neuberg D, Hochberg EP, Brown JR, Abramson JS.

Leuk Lymphoma. 2019 Dec;60(12):2931-2938. doi: 10.1080/10428194.2019.1608533. Epub 2019 May 10.

PMID:
31074316
37.

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.

Lampson BL, Kim HT, Davids MS, Abramson JS, Freedman AS, Jacobson CA, Armand PA, Joyce RM, Arnason JE, Rassenti LZ, Kipps TJ, Fein J, Fernandes SM, Hanna JR, Fisher DC, Brown JR.

Blood Adv. 2019 Apr 9;3(7):1167-1174. doi: 10.1182/bloodadvances.2018030221.

38.

The opportunity cost of walking away in the spatial iterated prisoner's dilemma.

Premo LS, Brown JR.

Theor Popul Biol. 2019 Jun;127:40-48. doi: 10.1016/j.tpb.2019.03.004. Epub 2019 Apr 1.

PMID:
30946861
39.

Biomarkers associated with 30-day readmission and mortality after pediatric congenital heart surgery.

Parker DM, Everett AD, Stabler ME, Vricella L, Jacobs ML, Jacobs JP, Thiessen-Philbrook H, Parikh CR, Brown JR.

J Card Surg. 2019 May;34(5):329-336. doi: 10.1111/jocs.14038. Epub 2019 Apr 3.

PMID:
30942505
40.

Claims-based surveillance for reintervention after endovascular aneurysm repair among non-Medicare patients.

Columbo JA, Sedrakyan A, Mao J, Hoel AW, Trooboff SW, Kang R, Brown JR, Goodney PP.

J Vasc Surg. 2019 Sep;70(3):741-747. doi: 10.1016/j.jvs.2018.11.031. Epub 2019 Mar 25.

PMID:
30922744
41.

Perceived risk for cancer progression and psychological status in chronic lymphocytic leukemia patients: CALGB 70603 (Alliance).

Deshields TL, Dueck AC, Rogers K, Brown JR, Shanafelt T, Mintzer D, Byrd JC.

Leuk Lymphoma. 2019 Oct;60(10):2580-2583. doi: 10.1080/10428194.2019.1594218. Epub 2019 Mar 27. No abstract available.

PMID:
30916608
42.

Are Urinary Biomarkers Better Than Acute Kidney Injury Duration for Predicting Readmission?

Brown JR, Thiessen-Philbrook H, Goodrich CA, Bohm AR, Alam SS, Coca SG, McArthur E, Garg AX, Parikh CR.

Ann Thorac Surg. 2019 Jun;107(6):1699-1705. doi: 10.1016/j.athoracsur.2019.02.005. Epub 2019 Mar 14.

PMID:
30880140
43.

Prebiotic supplementation in frail older people affects specific gut microbiota taxa but not global diversity.

Tran TTT, Cousin FJ, Lynch DB, Menon R, Brulc J, Brown JR, O'Herlihy E, Butto LF, Power K, Jeffery IB, O'Connor EM, O'Toole PW.

Microbiome. 2019 Mar 13;7(1):39. doi: 10.1186/s40168-019-0654-1.

44.

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.

Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JR.

Blood. 2019 May 9;133(19):2031-2042. doi: 10.1182/blood-2018-08-870238. Epub 2019 Mar 6.

PMID:
30842083
45.

Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.

O'Brien SM, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM, Barrientos JC, Devereux S, Robak T, Reddy NM, Kipps TJ, Tedeschi A, Cymbalista F, Ghia P, Chang S, Ninomoto J, James DF, Burger JA.

Am J Hematol. 2019 May;94(5):554-562. doi: 10.1002/ajh.25436. Epub 2019 Mar 8.

46.

Biomarkers for the prediction of cardiac readmission.

Parker DM, Brown JR.

Biomark Med. 2019 Feb;13(2):55-58. doi: 10.2217/bmm-2018-0381. Epub 2019 Jan 23. No abstract available.

47.

Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL.

Brown JR, O'Brien S, Kingsley CD, Eradat H, Pagel JM, Hirata J, McIver T, Morariu-Zamfir R, Kipps TJ.

Blood. 2019 Feb 28;133(9):990-992. doi: 10.1182/blood-2018-06-857714. Epub 2018 Dec 28. No abstract available.

PMID:
30593446
48.

Inconsistent Inferences.

Ramkumar N, Brown JR.

Circ Cardiovasc Qual Outcomes. 2018 Dec;11(12):e005235. doi: 10.1161/CIRCOUTCOMES.118.005235. No abstract available. Erratum in: Circ Cardiovasc Qual Outcomes. 2019 Feb;12(2):e000053.

PMID:
30562076
49.

Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.

Davids MS, Kim HT, Nicotra A, Savell A, Francoeur K, Hellman JM, Bazemore J, Miskin HP, Sportelli P, Stampleman L, Maegawa R, Rueter J, Boruchov AM, Arnason JE, Jacobson CA, Jacobsen ED, Fisher DC, Brown JR; Blood Cancer Research Partnership of the Leukemia and Lymphoma Society.

Lancet Haematol. 2019 Jan;6(1):e38-e47. doi: 10.1016/S2352-3026(18)30196-0. Epub 2018 Dec 14.

PMID:
30558987
50.

DUO delivers for duvelisib.

Brown JR.

Blood. 2018 Dec 6;132(23):2422-2424. doi: 10.1182/blood-2018-10-879650. No abstract available.

Supplemental Content

Loading ...
Support Center